Haohai Biological Technology to be included in Shanghai-Hong Kong Stock Connect, effective of February 1

Haohai Biological Technology（688366.SH，06826.HK）will be included in Shanghai Stock Connect and Hong Kong Stock Connect as of February 1!

On January 22, Shanghai Stock Exchange issued its newly-revised “Measures of Shanghai Stock Exchange for Implementation of Shanghai-Hong Kong Stock Connect Business”, effective as of February 1, 2021. The revision mainly consists of two aspects: firstly, specifying the appropriateness requirements for trading of SSE STAR Market shares by Shanghai Stock Connect investors, i.e., only institutional professional investors that meet the requirements defined in related rules of Hong Kong can participate in STAR Market stock trading through Shanghai Stock Connect; secondly, H shares of A+H share companies listed on Shenzhen Stock Exchange are included in the scope of Hong Kong Stock Connect stocks under the SH-HK Stock Connect.

Meanwhile, as of February 1, STAR Market stocks that are constituent stocks of SSE 180 Index and SSE 380 Index and A shares of A+H share companies will be officially included in the scope of stocks of Shanghai Stock Connect; H shares of A+H share companies listed on the STAR Market and H shares of A+H share companies listed on Shenzhen Stock Exchange will be officially included in the scope of Hong Kong Stock Connect stocks.

This also means that Haohai Biological Technology will be included in both Shanghai Stock Connect and Hong Kong Stock Connect as of February 1. As a high-tech biopharmaceutical company that has been growing up benefiting from the opening-up policies of capital markets, Haohai Biological Technology was successfully listed on the Main Board of The Stock Exchange of Hong Kong Ltd on April 30, 2015 and then listed on the STAR Market on October 30, 2019, becoming the first biopharmaceutical company to be listed on “H+STAR Market”. In the future, Haohai Biological Technology will continue upholding its business philosophy of “hard work, innovation and development”, create a high-quality listed company on the Chinese capital markets across the board and reciprocate its investors and the wider society with a more outstanding business performance.